Patient's way from acute pulmonary embolism to chronic thromboembolic pulmonary hypertension: diagnostic and treatment options
Authors:
Open Access
- 15 August 2019
- journal article
- review article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 91 (8) , 108-114
Abstract
Сhronic thromboembolic pulmonary hypertension (CTEPH) is a serious, under-diagnosed but potentially curable complication of pulmonary embolism (PE) due to medicine advancements. Lack of specific symptoms and signs makes its diagnosis challenging, requiring clinicians to be ready to suspect its presence in patients with dyspnea of unknown origin or persistent symptoms after the pulmonary embolism event. The success of the treatment of this disease depends entirely on early diagnosis. The complexity of the differential diagnosis is due to the problematic aspects including the lack of doctors' awareness of both the pathology itself and the possibilities of its modern treatment. Recently, in our country, the problem of the availability of expert centers with sufficient experience in providing highly specialized medical care to this rather difficult category of patients who need specific therapy has become very actual. The aim of this review is to provide contemporary information about epidemiology, pathophysiology, and clinical features of treating patients with CTEPH, and also, to increase awareness of potential PE→CTEPH transformation. In the article a 4-year-period of experience of the Meshalkin National Medical Research Center on management of CTEPH patients has been presented. Keywords: pulmonary embolism, chronic thromboembolic pulmonary hypertension, pulmonary endarterectomy, PAH-specific therapyKeywords
This publication has 11 references indexed in Scilit:
- Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients with diagnosis of pulmonary embolism for the first time in real worldThe Clinical Respiratory Journal, 2018
- Incidence and risk factors of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a systematic review and meta-analysis of cohort studiesJournal of Thoracic Disease, 2018
- EXPERIENCE OF OUTPATIENT CENTER FOR PULMONARY HYPERTENSION IN THE SAMARA REGIONComplex Issues of Cardiovascular Diseases, 2018
- Riociguat and sildenafil for pulmonary hypertension: similarity and differencePULMONOLOGIYA, 2016
- “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS).” Nazzareno Galiè, Marc Humbert, Jean-Luc Vachiery, Simon Gibbs, Irene Lang, Adam Torbicki, Gérald Simonneau, Andrew Peacock, Anton Vonk Noordegraaf, Maurice Beghetti, Ardeschir Ghofrani, Miguel Angel Gomez Sanchez, Georg Hansmann, Walter Klepetko, Patrizio Lancellotti, Marco Matucci, Theresa McDonagh, Luc A. Pierard, Pedro T. Trindade, Maurizio Zompatori and Marius Hoeper. Eur Respir J 2015; 46: 903–975.European Respiratory Journal, 2015
- 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolismEuropean Heart Journal, 2014
- Risk factors for chronic thromboembolic pulmonary hypertensionEuropean Respiratory Journal, 2008
- Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary EmbolismNew England Journal of Medicine, 2004
- Inhaled iloprost for severe pulmonary hypertensionACC Current Journal Review, 2002
- Prognoses of Primary Pulmonary Hypertension and Chronic Majorvessel Thromboembolic Pulmonary Hypertension Determined from Cumulative Survival Curves.Internal Medicine, 1999